Instem welcomes Mary Dolson to its Board as Independent Director

– UK, Stone –  Instem plc (LON: INS), a leading provider of IT solutions to the global life sciences market, today announced the appointment of Mary Dolson to its Board as an Independent Non-Executive Director, effective 9 January 2023.

“We are delighted to welcome Mary to the Board of Instem as an Independent Non-Executive Director. To have the support of someone with such unequivocal financial and industry expertise will be invaluable in helping the Company and Board realise its aspirations, and her joining the Board is undoubtedly a testament to where Instem has progressed to today. Mary’s experience is comprehensive, and she is perfectly suited, having worked extensively in the UK and US, to advise on the challenges and opportunities that we encounter,” said CEO, Phil Reason.

Mary Dolson will also join the Audit Committee as its Chair, and the Remuneration and Nomination Committees as a member.

About Mary Dolson

Mary Dolson is an expert advisor on regulatory, financial, and accounting compliance issues, with extensive experience advising businesses in the pharmaceutical, biotech, and life science sectors. She is a specialist and experienced advisor in taking companies through periods of change, from start-ups to venture capital investments to public offerings.

Most recently, Mary Dolson was a Non-Executive Director at Nuvelution Pharma Inc (Boston, USA) between 2019 and 2021, where she consulted as an expert in finance, modeling, and risk across all phases of the pharmaceutical and biotech industry.

Mary Dolson has spent most of her career in audit and served as a PwC partner in London for over 20 years, where she became the Global Lead on pharmaceutical industry accounting and reporting before retiring in 2018. Mary was a founding member of the ‘Pharma Forum’, an industry-based International Financial Reporting Standards working group.

Mary served as a Non-Executive Committee Member for the Financial Reporting Review Panel (UK), a position she held from 2011 until 31 December 2020 (when it was dissolved). In this role, Mary helped to guide the implementation of accounting standards, corporate governance, and other reporting codes.

Mary is a Bachelor of Business Accounting graduate of Pace University, Lubin School of Business, New York, and a Certified Public Accountant in the State of New York.

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are used by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring the life enhancing products to market faster. Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem’s platform during their development.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.